| Literature DB >> 31370388 |
Michaela Plath1, Hannah M Thielen1, Ingo Baumann1, Karim Zaoui1, Philippe A Federspil1.
Abstract
OBJECTIVES: The reconstruction after nasal skin cancer (NSC) resection is often practiced differently. The objective of this study is to evaluate the influence of patient-, tumor- and management-related factors on the role of surgery and choice of reconstruction.Entities:
Keywords: Bone-Anchored Prosthesis; Nasal Surgical Procedures; Quality of Life; Skin Neoplasms; Surgical Oncology
Year: 2019 PMID: 31370388 PMCID: PMC7248604 DOI: 10.21053/ceo.2019.00192
Source DB: PubMed Journal: Clin Exp Otorhinolaryngol ISSN: 1976-8710 Impact factor: 3.372
Surgical and clinicopathological characteristics of the study population
| Characteristics | Entire cohort (n=25) | Prosthesis cohort (PR, n=7) | Reconstruction cohort (SR, n=18) |
|---|---|---|---|
| Age (yr) | 73 (52–93) | 85 (74–92) | 68 (52–93) |
| Sex | |||
| Male | 15 (60.0) | 3 (42.9) | 12 (66.7) |
| Female | 10 (40) | 4 (57.1) | 6 (33.3) |
| Histology | |||
| BCC | 20 (80) | 5 (71.4) | 15 (83.3) |
| cSCC | 5 (20) | 2 (28.6) | 3 (16.7) |
| T stage | |||
| T1/2 | 17 (68.0) | 3 (42.9) | 14 (77.8) |
| T3/4 | 8 (32.0) | 4 (57.1) | 4 (22.2) |
| N stage | |||
| N0 | 25 (100) | 7 (100) | 18 (100) |
| M stage | |||
| M0 | 25 (100) | 7 (100) | 18 (100) |
| Questionnaire (FROI-17, ROE, and SF-36) | |||
| No response | 7 (28.0) | 1 (14.3) | 6 (33.3) |
| Response | 11 (44.0) | 2 (28.6) | 9 (50.0) |
| Excluded due to death | 7 (28.0) | 4 (57.1) | 3 (16.7) |
| 5-Year overall survival rate (%) | 69.5 | 53.6 | 77.2 |
| 5-Year disease-specific survival rate (%) | 100 | 100 | 100 |
| 5-Year recurrence-free survival rate (%) | 90.9 | 100 | 85.7 |
Values are presented as mean (range) or number (%).
PR, prosthetic rehabilitation; SR, surgical reconstruction; BCC, basal cell carcinomas; cSCC, cutaneous squamous cell carcinomas; FROI-17, Functional Rhinoplasty Outcome Inventory 17; ROE, Rhinoplasty Outcome Evaluation; SF-36, 36-Item Short Form Health Survey.
Fig. 1.(A-C) Partial rhinectomy and reconstruction with a paramedian forehead flap, anterior based septal mucoperichondrious flap, and cartilage graft. (D-F) Total rhinectomy followed by reconstruction with an implant-retained nasal prosthesis (nasal plate of the Epiplating System by Medicon eG, Tuttlingen, Germany; anaplastologist Jörn Brom, Heidelberg, Germany).
Fig. 2.Kaplan-Maier plots for overall survival (OS) and recurrence-free survival (RFS) depending on T1/2 vs. T3/4, basal cell carcinoma (BCC) vs. cutaneous squamous cell carcinoma (cSCC), prosthetic rehabilitation (PR) vs. surgical reconstruction (SR). Disease-specific survival was 100% (not shown).
FROI-17, ROE, and SF-36 scales
| Variable | Prosthetic rehabilitation (n=7) | Surgical reconstruction (n=18) | |
|---|---|---|---|
| FROI-17 | |||
| Overall score | 15.0±0.0 | 25.6±29.2 | 0.750 |
| Nasal symptom | 10.0±12.4 | 22.2±20.8 | 0.610 |
| General symptom | 20.0±14.4 | 21.4±29.1 | 0.965 |
| Self-confidence | 0.0±0.0 | 20.0±32.7 | 0.588 |
| ROE | 79.2±0.0 | 72.4±20.6 | 0.766 |
| SF-36 | |||
| Physical functioning | 55.0±35.4 | 73.3±30.4 | 0.469 |
| Physical role functioning | 50.0±70.7 | 66.7±50.0 | 0.695 |
| Bodily pain | 94.4±7.9 | 72.8±31.5 | 0.378 |
| General health | 52.5±3.5 | 64.4±26.2 | 0.558 |
| Vitality | 55.0±0.0 | 70.0±28.9 | 0.640 |
| Social functioning | 43.8±8.8 | 50.0±11.6 | 0.503 |
| Emotional role functioning | 66.7±47.1 | 79.2±39.6 | 0.707 |
| Mental health | 72.0±0.0 | 69.0±16.0 | 0.864 |
| FROI-17 | |||
| Overall score | 25.8±29.1 | 13.8±0.0 | 0.717 |
| Nasal symptom | 21.7±21.2 | 13.3±0.0 | 0.730 |
| General symptom | 26.3±29.7 | 6.3±8.8 | 0.404 |
| Self-confidence | 21.7±35.4 | 5.0±7.1 | 0.553 |
| ROE | 70.8±20.1 | 81.3±20.6 | 0.541 |
| SF-36 | |||
| Physical functioning | 61.9±31.7 | 91.7±10.4 | 0.044 |
| Physical role functioning | 62.5±51.8 | 66.7±57.7 | 0.910 |
| Bodily pain | 72.2±33.6 | 88.9±11.1 | 0.248 |
| General health | 57.1±25.5 | 73.3±17.6 | 0.352 |
| Vitality | 63.3±30.9 | 78.3±20.2 | 0.478 |
| Social functioning | 48.2±13.4 | 50.0±0.0 | 0.829 |
| Emotional role functioning | 66.7±43.0 | 100.0±0.0 | 0.086 |
| Mental health | 66.0±17.7 | 76.0±4.0 | 0.380 |
| SF-36 | |||
| Physical functioning | 70.0±30.3 | 84.2±23.8 | 0.049 |
| Physical role functioning | 63.6±50.5 | 80.6±34.5 | 0.292 |
| Bodily pain | 76.8±29.6 | 77.0±28.5 | 0.978 |
| General health | 62.0±23.7 | 64.1±23.5 | 0.777 |
| Vitality | 68.3±27.5 | 61.9±19.1 | 0.316 |
| Social functioning | 48.8±10.9 | 87.7±19.5 | <0.001 |
| Emotional role functioning | 76.7±38.7 | 87.7±29.0 | 0.228 |
| Mental health | 69.3±15.0 | 72.9±17.2 | 0.541 |
Values are presented as mean±standard deviation.
FROI-17, ROE, and SF-36 scales after prosthetic rehabilitation (n=7) vs. surgical reconstruction (n=18) in all patients (T1-4), BCC (n=20) vs. cSCC patients (n=5), and NSC cohort (n=25) vs. the normally distributed SF-36 reference population (n=2,900). A higher ROE score indicates higher satisfaction. A higher FROI-17 score indicates lower satisfaction. P<0.05 were considered statistically significant.
FROI-17, Functional Rhinoplasty Outcome Inventory 17; ROE, Rhinoplasty Outcome Evaluation; SF-36, 36-Item Short Form Health Survey; SD, standard deviation; BCC, basal cell carcinomas; cSCC, cutaneous squamous cell carcinomas; NSC, nasal skin cancer.
Fig. 3.Box-plot analysis showing the 36-Item Short Form Health Survey (SF-36) subscores (P<0.05) comparing sub-cohort (cutaneous squamous cell carcinoma [cSCC] versus basal cell carcinoma [BCC]; surgical reconstruction versus prosthetic rehabilitation, T1/2 versus T3/4, and in the SF-36 to the norm-distributed patient cohort). A higher SF-36 score indicates higher satisfaction. Only significant differences are presented. NSC, nasal skin cancer.
Comparison of advantage and disadvantage in prosthetic rehabilitation versus surgical reconstruction
| Variable | Prosthetic rehabilitation | Surgical reconstruction |
|---|---|---|
| Advantage | • Simple and fast surgical procedure for implant placeme (operating time approximately 20–30 minutes) | • Psychological benefit of using patient’s own tissue |
| • No donor site morbidity/scars | • No need for maintenance or specialized care | |
| • Short rehabilitation time (fitting after a healing period of 6 | • Defect is eliminated and no longer visible. | |
| • Predictable cosmesis of prosthesis | • Follows color change of adjacent skin with temperature, emotion and sun exposure | |
| • Prosthesis may be changed according to patient wishes. | ||
| • Ease of oncological follow-up to detect local recurrence | ||
| Disadvantage | • Prothesis is a “foreign body.” | • Multiple stages of surgical reconstruction under general anesthesia with longer operation time |
| • Patients keep the defect. | • Longer healing time with three surgical stages of 3–6 months | |
| • Risk of losing the prosthesis with inadvertent contact | • Possible surgical complications with reconstruction, especially in irradiated patients and smokers | |
| • Prosthesis is removed for sleeping (patient wears a light bandage). | • Possible need for secondary refinement surgery | |
| • Prosthesis may exhibit color mismatch with seasonal cha complexion or cigarette smoke. | • Additional scars outside the nasal region | |
| • Necessity of a new prosthesis every 2 years due to degr and/or slight defect changes | • Malignant precursor lesion may be transposed (field cancerization with UV exposure). | |
| • Cost for initial and repetitive manufacturing | • Cosmetic result less predictable | |
| • Personal hygiene for percutaneous parts of implants (however minimal for nasal implants) | • Oncological follow-up less easy (may need endoscopy and imaging) | |
| • Magnets have to be temporarily removed for MRI (titanium implants are MRI conditional). |
UV, ultraviolet; MRI, magnetic resonance imaging.